Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINCERE: Salvage Immunotherapy with Chemotherapy in Esophageal Squamous Cell Carcinoma
NCT05103501Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05103501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103501.